Scarica l'app Stockscreener
1.345
2.54%
-0.035
Precedente Chiudi:
$1.38
Aprire:
$1.39
Volume 24 ore:
1.75M
Relative Volume:
2.06
Capitalizzazione di mercato:
$85.08M
Reddito:
$139.77M
Utile/perdita netta:
$-97.62M
Rapporto P/E:
-0.8513
EPS:
-1.58
Flusso di cassa netto:
$-61.71M
1 W Prestazione:
-12.09%
1M Prestazione:
-6.60%
6M Prestazione:
-7.24%
1 anno Prestazione:
-60.32%
Intervallo 1D:
$1.3245
$1.40
Intervallo di 1 settimana:
$1.3245
$1.51
Portata 52W:
$0.9897
$3.64
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Confronta MGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.345 | 87.30M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.24 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
721.84 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.45 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
896.39 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.09 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
Wall Street analysts’ outlook for Macrogenics Inc (MGNX) - Setenews
What analysts say about MacroGenics Inc stockReal-Time Stock Alerts & Free Tremendous Portfolio Expansion - earlytimes.in
MacroGenics (NASDAQ:MGNX) Shares Cross Below 200-Day Moving Average – Here’s What Happened - Defense World
IM Cannabis (NASDAQ:IMCC) & MacroGenics (NASDAQ:MGNX) Head to Head Survey - Defense World
Macrogenics (MGNX) Stock Analysis Report | Financials & Insights - Benzinga
MGNX (Macrogenics) EPS without NRI : $-1.20 (TTM As of Sep. 2025) - GuruFocus
MGNX (Macrogenics) Operating Cash Flow per Share : $-2.58 (TTM As of Sep. 2025) - GuruFocus
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference - Enidnews.com
Taking the lead: Macrogenics Inc (MGNX) - Setenews
Is MacroGenics Inc. stock cheap at current valuationEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
Is MacroGenics Inc. stock positioned for digital transformation2025 AllTime Highs & Daily Volume Surge Trade Alerts - newser.com
Will MacroGenics Inc. stock recover faster than peersForecast Cut & Free Growth Oriented Trading Recommendations - newser.com
MacroGenics Announces Departure of Chief Medical Officer - TipRanks
Why MacroGenics Inc. stock attracts high net worth investorsGap Up & Weekly Setup with High ROI Potential - newser.com
Is MacroGenics Inc. stock attractive for passive investorsLong Setup & Expert Verified Movement Alerts - newser.com
Will MacroGenics Inc. stock continue dividend increasesEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
What MACD and RSI say about MacroGenics Inc.2025 Year in Review & Risk Managed Investment Entry Signals - newser.com
Automated trading signals detected on MacroGenics Inc.Inflation Watch & Safe Entry Point Identification - newser.com
Ranking MacroGenics Inc. among high performing stocks via toolsSell Signal & Community Consensus Trade Alerts - newser.com
Will MacroGenics Inc. stock recover after recent drop2025 Technical Overview & Safe Capital Growth Tips - newser.com
Comparing MacroGenics Inc. in custom built stock radarsJuly 2025 Highlights & AI Forecast Swing Trade Picks - newser.com
FY2025 EPS Estimates for MacroGenics Increased by Analyst - Defense World
MacroGenics, Inc. Reports Decline in Quarterly Revenues - TipRanks
MacroGenics’s SWOT analysis: biotech stock faces pivotal moment amid pipeline shifts - Investing.com Canada
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Macrogenics Inc Azioni (MGNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HEIDEN WILLIAM K | Director |
Aug 20 '25 |
Buy |
1.49 |
49,500 |
73,755 |
111,000 |
| Koenig Scott | Director |
Aug 13 '25 |
Option Exercise |
0.00 |
52,829 |
0 |
830,244 |
| Bonvini Ezio | Sr VP, Research & CSO |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
124,414 |
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
0.83%
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):